Aisha I Abdullah PhD,  —

An investigational compound that targets dysfunctional or improperly working autophagy — the removal of unnecessary or damaged cell components — may improve that process and reduce inflammation in a mouse model of Sanfilippo syndrome. However, the compound did not reduce heparan sulfate accumulation or lessen behavioral…

Editor’s Note: This story was updated on March 24, 2021, to include information about setbacks and safety concerns related to the AAVance trial. LYS-SAF302, Lysogene’s experimental gene therapy for Sanfilippo syndrome type A, effectively lowered the levels of three disease biomarkers — GM2, GM3, and heparan sulfate…

All nine Sanfilippo type A patients analyzed to date in the ongoing Phase 2/3 clinical trial of the gene therapy LYS-SAF302 show reductions in the levels of heparan sulfate (HS), Lysogene, the therapy’s developer, reported. These reductions were specifically observed in…

Looking at the tissue of the retina — the innermost, light-sensitive layer of the eye — may be a way to monitor Sanfilippo progression and treatment outcomes, a study has found. In a mouse model of the disease retinal lesions emerged very early, even before the appearance of…